D-Index & Metrics Best Publications

Anna Sureda

Autonomous University of Barcelona
Spain

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 85 Citations 23,884 639 World Ranking 9670 National Ranking 132

Overview

What is she best known for?

The fields of study Anna Sureda is best known for:

Lymphoma
Follicular lymphoma
CD20

Anna Sureda performs multidisciplinary study on Internal medicine and Family medicine in her works. Family medicine and Internal medicine are two areas of study in which she engages in interdisciplinary work. She conducts interdisciplinary study in the fields of Lymphoma and CD20 through her works. Anna Sureda merges CD20 with Lymphoma in her study. Anna Sureda integrates several fields in her works, including Oncology and Gastroenterology. She carries out multidisciplinary research, doing studies in Gastroenterology and Oncology. Her research on Refractory (planetary science) frequently links to adjacent areas such as Astrobiology. Astrobiology and Refractory (planetary science) are commonly linked in her work. Anna Sureda combines Multidisciplinary approach and Social science in her studies.

Her most cited work include:

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study (82 citations)
ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma (56 citations)

What are the main themes of her work throughout her whole career to date

Daratumumab, Carfilzomib and Pomalidomide are the main topics of her Lenalidomide study. As part of her studies on Daratumumab, Anna Sureda frequently links adjacent subjects like Bortezomib. In her papers, Anna Sureda integrates diverse fields, such as Bortezomib and Thalidomide. In her works, Anna Sureda undertakes multidisciplinary study on Thalidomide and Lenalidomide. As part of her studies on Pomalidomide, Anna Sureda often connects relevant areas like Multiple myeloma. She performs multidisciplinary study in Multiple myeloma and Carfilzomib in her work. Anna Sureda integrates Internal medicine with Family medicine in her research. Anna Sureda brings together Family medicine and Internal medicine to produce work in her papers. Oncology and Gastroenterology are two areas of study in which Anna Sureda engages in interdisciplinary research.

Anna Sureda most often published in these fields:

Internal medicine (100.00%)
Oncology (80.00%)
Astrobiology (60.00%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Craig H. Moskowitz;Auayporn Nademanee;Tamas Masszi;Edward Agura.
The Lancet (2015)

703 Citations

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Bruno Paiva;Maria-Belén Vidriales;Jorge Cerveró;Gema Mateo.
Blood (2008)

478 Citations

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.

P. Ljungman;M. Bregni;M. Brune;J. Cornelissen.
Bone Marrow Transplantation (1998)

463 Citations

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually

Jakob Passweg;H. Baldomero;P. Bader;Chiara Bonini.
Bone Marrow Transplantation (2016)

458 Citations

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge.
The Lancet (2019)

445 Citations

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Anna Sureda;Stephen Robinson;Carmen Canals;Angelo M. Carella.
Journal of Clinical Oncology (2008)

400 Citations

Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.

Alois Gratwohl;Martin Stern;Ronald Brand;Jane Apperley.
Cancer (2009)

377 Citations

Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

Juan José Lahuerta;Maria Victoria Mateos;Joaquin Martínez-López;Laura Rosiñol.
Journal of Clinical Oncology (2008)

376 Citations

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015

A. Sureda;P. Bader;S. Cesaro;P. Dreger.
Bone Marrow Transplantation (2015)

374 Citations

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Bruno Paiva;Norma C. Gutiérrez;Laura Rosiñol;María-Belén Vídriales.
Blood (2011)

368 Citations

If you think any of the details on this page are incorrect, let us know.